A Study of TCR Engineered Donor T Cells in Leukemia Patients Haploidentical Allogeneic Stem Cell Transplantation
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1
interventional, open-label, biologic assignment-based umbrella study evaluating the
feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses
of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical
donor.